A recent study conducted in mice found that the ability of cells to use glucose can actually help to regulate the immune system during lung inflammation.
In the United States and around the world, millions of people live with chronic respiratory conditions, such as asthma and COPD. According to HHS' Office of Disease Prevention and Health Promotion, asthma currently affects 25 million US citizens, while 14.8 million adults have been diagnosed with COPD.
A recent study conducted in mice found that the ability of cells to use glucose can actually help to regulate the immune system during lung inflammation.
Researchers identified that the lungs’ macrophages had “unexpected” reactions to glucose. The authors reported that stimulating the cells with more sugar could help the immune system fight off bronchial infections that lead to pneumonia or intense coughs.
“Hundreds of people are admitted to hospital[s] every day in the [United Kingdom] with asthma attacks, while potentially deadly parasitic infections in the lungs are endemic across much of Africa and Asia. The idea that modifying glucose levels in the lungs could one day be a critical factor in treatment of these conditions is tremendously exciting,” study author, Andrew MacDonald, BSc, PhD, professor at the University of Manchester, said in a statement.
The researchers were able to determine that macrophages need the correct levels of glucose in order to be able to function properly. The team used interleukin 4, which is a protein typically found during inflammation caused by asthma or a parasitic worm infection, to test the association between macrophages and glucose.
Specifically, the authors were able to identify 2 significant results: blocking sugar receptors in the lung may help to reduce inflammation in chronic respiratory conditions, and conversely, boosting glucose levels in the lung could facilitate an immune response in patients with certain respiratory infections.
“During inflammation of the type seen in asthma and parasitic worm infection it appears that glucose, and the use of glucose, controls macrophage activation in the lungs. Clearly, we now need to study the impact of glucose on human lung macrophages,” said MacDonald.
MacDonald also suggested that there’s potential for a glucose receptor-based drug treatment in the future. “It’s reasonable to suggest that short-term inhalation therapy might one day work as such a treatment,” he said.
Reference
Svedberg F, Brown S, Krauss M, et al. The lung environment controls alveolar macrophage metabolism and responsiveness in type 2 inflammation [published online April 1, 2019]. Nat Immunol. doi: 10.1038/s41590-019-0352-y
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More